Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.

Dermatol Ther · 2022 · PMC10078391 · PMID 36209377

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

revealed the potential benefit of the Q2W dosing in some suboptimal responders but did not reach statistical significance compared with the Q4W dose. 13 Another therapeutic administered without the initial weekly loading dose was inferior to secukinumab at the labeled dose. 14 The feasibility of gradually increasing the dosing interval of secukinumab for treatment is still unknown.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.